Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2158-2165

  Madic, Jordan ^a,b   Kiialainen, Anna ^c   Bidard, Francois Clement ^a   Birzele, Fabian ^c   Ramey, Guillemette ^d   Leroy, Quentin ^a   Frio, Thomas Rio ^a   Vaucher, Isabelle ^a   Raynal, Virginie ^b   Bernard, Virginie ^a   Lermine, Alban ^e   Clausen, Inga ^c   Giroud, Nicolas ^c   Schmucki, Roland ^c   Milder, Maud ^a,f   Horn, Carsten ^c   Spleiss, Olivia ^c   Lantz, Olivier ^a,f,g   Stern, Marc Henri ^a,b   Pierga, Jean Yves ^a,h   Weisser, Martin ⁱ   Lebofsky, Ronald ^a   more..

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Institut Roche de Recherche et Médecine Translationnelle   (France)

^e INSERM U900   (France)

^f INSERM   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Circulating tumor cells; Circulating tumor DNA; Next generation sequencing; TP53; Triple negative breast cancer

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; DNA; LACTATE DEHYDROGENASE; PROTEIN P53; UNCLASSIFIED DRUG; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; HUMAN; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; BLOOD; DISEASE COURSE; FEMALE; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM;

DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; HUMANS; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923164411     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29265     Document Type: Article

References (25)

1. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med 2010;7: E1000279.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363: 1938-48.
3. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012;486: 395-9.
4. Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: From circulating tumor cells to DNA. Sci Transl Med 2013;5: 207ps14.
5. Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol 2014;15: 406-14.
6. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-And latestage human malignancies. Sci Transl Med 2014; 6: 224ra24.
7. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11: 426-37.
8. Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 2014;134: 1207-13.
9. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368: 1199-209.
10. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14: 985-90.
11. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4: 136ra68.
12. Holstege H, Joosse SA, van Oostrom CT, et al. High incidence of protein-Truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009;69: 3625-33.
13. Langerod A, Zhao H, Borgan O, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9: R30.
14. Manie E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009;69: 663-71.
15. Pierga JY, Bidard FC, Cropet C, et al. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: The LANDSCAPE trial. Ann Oncol 2013;24: 2999-3004.
16. Rago C, Huso DL, Diehl F, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 2007;67: 9364-70.
17. Madic J, Piperno-Neumann S, Servois V, et al. Pyrophosphorolysis-Activated polymerization detects cir-culating tumor DNA in metastatic uveal melanoma. Clin Cancer Res 2012;18: 3934-41.
18. Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25: 2078-9.
19. Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014; 20: 2643-50.
20. Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013;59: 1722-31.
21. Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 2011;108: 9530-5.
22. Hiatt JB, Pritchard CC, Salipante SJ, et al. Single molecule molecular inversion probes for targeted, high-Accuracy detection of low-frequency variation. Genome Res 2013;23: 843-54.
23. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-And latestage human malignancies. Sci Transl Med 2014; 6: 224ra24.
24. Murtaza M, Dawson SJ, Tsui DW, et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497: 108-12.
25. Heidary M, Auer M, Ulz P, et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 2014;16: 421.